NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

Meanwhile, WuXi Vaccines, a subsidiary of WuXi Biologics, says it will sell a vaccine facility in Dundalk, Ireland, to the US drugmaker Merck & Co. for $521 million. WuXi Biologics says the sale ...

China's WuXi Biologics has announced plans to sell its vaccine facility in Ireland to U.S. pharmaceutical giant Merck & Co. for approximately USD 500 million. The decision comes ahead of potential U.S ...

(Borrell, 1/7) Reuters: China's WuXi Biologics To Sell Irish Vaccine Facility To Merck As US Curbs Loom China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S.

WuXi Biologics (HKEX: 2269), today announced a definitive agreement with Merck & Co’s (NYSE: MRK) MSD International GmbH unit, whereby the latter will acquire WuXi Vaccines’ facility in Dundalk, ...

Although the newsthat WuXi Bio sold its Ireland vaccine facility to Merck (MRK) for about $500M sent the stock lower, the firm thinks the company sold the facility not mainly due to “Biosecure ...

Meanwhile, China's WuXi Biologics intends to sell its Irish vaccine facility to Merck & Co for $500 million, ahead of impending U.S. legislation restricting Chinese biotech firms' operations. The ...

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would limit business for Chinese biotech companies ...

Over 3,000 people are employed across the network. Merck and WuXi Vaccines are now entering a formal handover process, expected to conclude in the first half of 2025. Once complete, the facility ...